Viking Therapeutics
VKTX
28.54
+0.16
+0.56%
Viking Therapeutics
US · VKTX
#2352 by market cap
Listed 2015
28.54
+0.16
+0.56%
Live - 5344 symbols - heartbeat 206s ago
· 2026-10-08 08:38
Pre-market
28.40
-0.49%
After-hours
28.62
+0.29%
Overnight
28.41
-0.46%
- Market cap
- 3.59B
- P/E (TTM)i
- -6.11
- P/Bi
- 8.78
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 16%
Reader sentiment
Are you bullish or bearish on VKTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 65.69% -0.02pp
- Institutions
- 504 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund43.74%
Hedge Fund12.06%
Public Company5.75%
Private Company3.17%
Individual/Insider2.46%
Government Pension Fund0.48%
Family Office/Trust0.21%
VC/PE Fund0.17%
Other31.89%
Top holders as of 2026-06-30
FMR
5.40% · 6.30M sh
BlackRock
5.31% · 6.19M sh
Vanguard Capital Management, LLC
4.96% · 5.79M sh
State Street Global Advisors
4.81% · 5.61M sh
Vanguard Portfolio Management, LLC
3.84% · 4.48M sh
Two Sigma Investments, LP
3.38% · 3.94M sh
Morgan Stanley
2.73% · 3.19M sh
Brian Lian
1.90% · 2.22M sh
Columbia Management Investment Advisers, LLC
1.85% · 2.16M sh
Geode Capital Management, LLC
1.80% · 2.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Brian Lian | Chief Executive Officer | 1.90% |
| Marianne Mancini | Chief Operating Officer | 0.27% |
| Matthew Foehr | Independent Director | 0.11% |
| Gregory Zante | Chief Financial Officer | 0.10% |
| Lawson MacArtney | Independent Chairperson | 0.04% |
| Charles Rowland | Independent Director | 0.03% |
| J. Singleton | Independent Director | 0.01% |
| Neil Aubuchon | Chief Commercial Officer | 0.00% |
| Sarah Rouan | Independent Director | 0.00% |
| Hubert Chen | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-31 | Dorothy Gemmell | Director | Other Acquisition | +6,333 | -- |
| 2026-07-31 | Dorothy Gemmell | Director | Other Derivative Acquisition | +40,800 | $31.74 |
| 2026-07-28 | Gregory Zante | Chief Financial Officer | Open Market Disposition | -21,217 | $33.47 |
| 2026-07-28 | Brian Lian | Chief Executive Officer | Open Market Disposition | -148,517 | $33.32 |
| 2026-07-28 | Marianne Mancini | Chief Operating Officer | Open Market Disposition | -18,217 | $33.47 |
| 2026-07-27 | Gregory Zante | Chief Financial Officer | Other Acquisition | +31,667 | -- |
| 2026-07-27 | Brian Lian | Chief Executive Officer | Other Acquisition | +221,667 | -- |
| 2026-07-27 | Marianne Mancini | Chief Operating Officer | Other Acquisition | +31,667 | -- |
| 2026-05-31 | Hubert Chen | Chief Medical Officer | Other Derivative Acquisition | +190,000 | $31.27 |
| 2026-03-09 | Neil Aubuchon | Chief Commercial Officer | Open Market Acquisition | +4,475 | $33.50 |
| 2026-01-11 | Neil Aubuchon | Chief Commercial Officer | Other Derivative Acquisition | +180,000 | $31.76 |
| 2026-01-04 | Gregory Zante | Chief Financial Officer | Other Acquisition | +41,000 | -- |
| 2026-01-04 | Gregory Zante | Chief Financial Officer | Open Market Disposition | -57,661 | $32.09–34.24 |
| 2026-01-04 | Brian Lian | Chief Executive Officer | Other Acquisition | +78,400 | -- |
| 2026-01-04 | Brian Lian | Chief Executive Officer | Open Market Disposition | -233,409 | $32.29–35.07 |
| 2026-01-04 | Marianne Mancini | Chief Operating Officer | Other Acquisition | +41,000 | -- |
| 2026-01-04 | Marianne Mancini | Chief Operating Officer | Open Market Disposition | -57,661 | $32.29–35.07 |
| 2026-01-01 | Matthew Foehr | Independent Director | Other Acquisition | +3,150 | -- |
| 2026-01-01 | Matthew Foehr | Independent Director | Derivative Exercise and Sale | -16,000 | $3.33–35.11 |
| 2026-01-01 | Matthew Foehr | Independent Director | Other Derivative Acquisition | +20,400 | $35.42 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:38:39 · For reference only, not investment advice and not tailored to your situation.